RT Journal Article
SR Electronic
T1 Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.04.21252532
DO 10.1101/2021.03.04.21252532
A1 Pelleau, Stéphane
A1 Woudenberg, Tom
A1 Rosado, Jason
A1 Donnadieu, Françoise
A1 Garcia, Laura
A1 Obadia, Thomas
A1 Gardais, Soazic
A1 Elgharbawy, Yasmine
A1 Velay, Aurelie
A1 Gonzalez, Maria
A1 Nizou, Jacques Yves
A1 Khelil, Nizar
A1 Zannis, Konstantinos
A1 Cockram, Charlotte
A1 Hélène Merkling, Sarah
A1 Meola, Annalisa
A1 Kerneis, Solen
A1 Terrier, Benjamin
A1 de Seze, Jerome
A1 Planas, Delphine
A1 Schwartz, Olivier
A1 Dejardin, François
A1 Petres, Stéphane
A1 von Platen, Cassandre
A1 Arowas, Laurence
A1 de Facci, Louise Perrin
A1 Duffy, Darragh
A1 Cheallaigh, Clíona Ní
A1 Conlon, Niall
A1 Townsend, Liam
A1 Auerswald, Heidi
A1 Backovic, Marija
A1 Hoen, Bruno
A1 Fontanet, Arnaud
A1 Mueller, Ivo
A1 Fafi-Kremer, Samira
A1 Bruel, Timothée
A1 White, Michael
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252532.abstract
AB Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a complex antibody response that varies by orders of magnitude between individuals and over time. Waning antibody levels lead to reduced sensitivity of serological diagnostic tests over time. This undermines the utility of serological surveillance as the SARS-CoV-2 pandemic progresses into its second year. Here we develop a multiplex serological test for measuring antibodies of three isotypes (IgG, IgM, IgA) to five SARS-CoV-2 antigens (Spike (S), receptor binding domain (RBD), Nucleocapsid (N), Spike subunit 2, Membrane-Envelope fusion) and the Spike proteins of four seasonal coronaviruses. We measure antibody responses in several cohorts of French and Irish hospitalized patients and healthcare workers followed for up to eleven months after symptom onset. The data are analysed with a mathematical model of antibody kinetics to quantify the duration of antibody responses accounting for inter-individual variation. One year after symptoms, we estimate that 36% (95% range: 11%, 94%) of anti-S IgG remains, 31% (9%, 89%) anti-RBD IgG remains, and 7% (1%, 31%) anti-N IgG remains. Antibodies of the IgM isotype waned more rapidly, with 9% (2%, 32%) anti-RBD IgM remaining after one year. Antibodies of the IgA isotype also waned rapidly, with 10% (3%, 38%) anti-RBD IgA remaining after one year. Quantitative measurements of antibody responses were used to train machine learning algorithms for classification of previous infection and estimation of time since infection. The resulting diagnostic test classified previous infections with 99% specificity and 98% (95% confidence interval: 94%, 99%) sensitivity, with no evidence for declining sensitivity over the time scale considered. The diagnostic test also provided accurate classification of time since infection into intervals of 0 – 3 months, 3 – 6 months, and 6 – 12 months. Finally, we present a computational method for serological reconstruction of past SARS-CoV-2 transmission using the data from this test when applied to samples from a single cross-sectional sero-prevalence survey.Competing Interest StatementMTW, IM, JR, SPel, MB, and SPet are inventors on provisional patent PCT/US 63/057.471 on a serological antibody-based diagnostics of SARS-CoV-2 infection. TB and OS are coinventors on provisional patent PCT/US 63/020,063 entitled S-Flow: a FACS-based assay for serological analysis of SARS-CoV-2 infection submitted by Institut Pasteur. SK reports personal fees from Accelerate Diagnostics, Astellas, Merck Sharp & Dohme, Pfizer, and Menarini, and grants and personal fees from bioMerieux, outside of the submitted work.Clinical TrialNAFunding StatementThis work was supported by the European Research Council (MultiSeroSurv ERC Starting Grant 852373; MW), l Agence Nationale de la Recherche and Fondation pour la Recherche Medicale (CorPopImm; MW), and the Institut Pasteur International Network (CoronaSeroSurv; MW). JR was supported by the Pasteur Paris University (PPU) International PhD Program. CC was supported by the European Research Council 771813. MB and AL were supported by the URGENCE COVID-19 fundraising campaign of Institut Pasteur. NC and CNC are part-funded by a Science Foundation Ireland (SFI) grant, Grant Code 20/SPP/3685. LT has been awarded the Irish Clinical Academic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland (https://icatprogramme.org/). MB and AM were supported by Institut Pasteur TaskForce funding (TooLab project).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serum samples were biobanked at the Clinical Investigation and Access to BioResources platform at Institut Pasteur (Paris, France). Samples were obtained from consenting individuals through the CORSER study (NCT04325646), directed by Institut Pasteur and approved by the Comite de Protection des Personnes Ile de France III, and the French COVID cohort (NCT04262921), sponsored by Inserm and approved by the Comite de Protection des Personnes Ile de France VI. Samples from French blood donors were approved for use by Etablissement Francais du Sang (Lille, France) and approved through the CORSER study by the Comite de Protection des Personnes Ile de France VI. Sample collection in Hopital Cochin was approved by the Research Ethics Commission of Necker-Cochin Hospital. Samples from healthcare workers in Strasbourg University Hospitals followed longitudinally were collected as part of an ongoing clinical trial (ClinicalTrials.gov Identifier: NCT04441684) which received ethical approval from the Comite de Protection des Personnes Ile de France III. Samples collected from patients in Dublin received ethical approval for study from the Tallaght University Hospital (TUH)/St James Hospital (SJH) Joint Research Ethics Committee (reference REC 2020-03). Use of the Peruvian negative controls was approved by the Institutional Ethics Committee from the Universidad Peruana Cayetano Heredia (SIDISI 100873). The Human Research Ethics Committee at the Walter and Eliza Hall Institute of Medical Research and the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Thailand, approved the use of the Thai negative control samples. Informed written consent was obtained from all participants or their next of kin in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code will be made available online following peer review of the article. In the meantime, requests for data or code should be made to the corresponding author.